Valeant Pharmaceuticals International Inc. posted a wider loss in its latest quarter, and the company said it would reorganize, continuing a push to remake itself as a conventional pharmaceutical firm. The company also affirmed its yearly guidance after a string of cuts, easing fears of triggering a debt-covenant breach. Shares in the company added 17% in midday trading to $26.28. It has been just over a full year since...

Source: Wall Street Journal August 09, 2016 10:31 UTC